2021
The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity
Kuchroo JR, Hafler DA, Sharpe AH, Lucca LE. The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. Science Immunology 2021, 6: eabf4034. PMID: 34739340, DOI: 10.1126/sciimmunol.abf4034.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsPD-1 blockadeRegulatory T cell functionImmune checkpoint blockadeCheckpoint blockade immunotherapyT cell responsesT cell functionBlockade immunotherapyAdverse eventsAntitumor immunityCheckpoint blockadeCell responsesBlockadeCell functionAutoimmunityMechanistic featuresEdged swordImmunotherapyTumorsCancerImmunity
1997
B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors.
Greenfield EA, Howard E, Paradis T, Nguyen K, Benazzo F, McLean P, Höllsberg P, Davis G, Hafler DA, Sharpe AH, Freeman GJ, Kuchroo VK. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. The Journal Of Immunology 1997, 158: 2025-34. PMID: 9036945, DOI: 10.4049/jimmunol.158.5.2025.Peer-Reviewed Original ResearchMeSH KeywordsAbataceptAnimalsAntigens, CDAntigens, DifferentiationB7-2 AntigenCD28 AntigensCell DivisionCTLA-4 AntigenFemaleImmunoconjugatesLymphocyte ActivationMembrane GlycoproteinsMiceMice, Inbred BALB CMice, Inbred C57BLProtein BindingThymomaThymus NeoplasmsT-LymphocytesTransfectionTumor Cells, Cultured